

FMCG

HOLD: 12M TP @ 22.50

Upside +8.75%

Valuation Summary (TTM)					
Price (SAR)	- aminary (I	,	20.69		
PER TTM (x)			8.1		
P/Book (x)			1.4		
P/Sales (x)			1.9		
EV/Sales (x)			1.5		
EV/EBITDA (x)			6.9		
Dividend Yield (%)			NA		
Free Float (%)			58%		
Shares O/S (mn)			302		
YTD Return (%)			-15%		
Beta			0.9		
(mn)		SAR	USD		
Market Cap		6,328	1,687		
Enterprise value		5,114	1,363		
Price performance (%)	1M	3M	12M		
NADEC	2%	3%	-24%		
Tadawul All Share Index	-2%	-4%	-12%		
Trading liquidity (,000)	1M	3M	6M		
Avg daily turnover (SAR)	9,200	14,547	24,020		
Avg Daily Volume (,000)	462	700	1,078		
52 week	High	Low	CTL*		
Price (SAR)	29.40	18.20	15.3		
* CTL is % change in CMP to	52wk low				
Major shareholders					
Saudi Agricultural a			39%		
Vanguard Group Inc/T			2.0%		
Blackrock Inc			0.9%		
Others			58.5%		
Other details					
Exchange		Saudi Arabia			
Sector			Food		
Index weight (%)			0.2%		
Keyratios	2022	2023	2024		
EPS (SAR)	0.45	1.00	2.57		
BVPS (SAR)	6.08	11.91	14.25		
DPS (SAR)	0.00	0.00	0.00		
Payout ratio (%)	0%	0%	0%		
40.0 -			- 80.0		



NADEC - Weak core segment; margins improve

NADEC reported 2Q25 revenue of SAR 830mn, up 5% YoY, but slightly below our estimate by 4%. For 1H25, revenue grew 11.79% YoY to SAR 1.84bn. Quarterly revenue growth was supported by stronger sales in agriculture and protein segments, partially offset by muted performance in the dairy and food segment. The company's focus on cost optimization contributed to margin improvement during the quarter.

Agriculture and protein segments drive growth: Agricultural revenue during the quarter grew 39.3% YoY to SAR 60mn, owing to increased sales volume and realization, accounting for 7% of total. The protein segment, also representing 7% of revenue, grew 35.1% YoY in 2Q25, driven by strategic expansions, the establishment of local slaughterhouses, and enhanced distribution networks. In contrast, the dairy and food segment, which makes up 91% of revenue, grew only 1.9% YoY, reflecting a decline in fresh milk demand and a shift toward lower-priced processed milk.

Margins supported despite higher costs: Gross profit rose 5% YoY to SAR 313mn, in line with revenue growth, as direct costs increased at the same rate. Gross margin therefore remained stable, declining only 10bps YoY to 37.7% in 2Q25. Selling and marketing expenses increased 6.5% YoY due to higher distribution costs, while administrative expenses rose 4% YoY. Impairment losses on trade receivables increased 20% YoY owing to higher receivable balances. Other income of SAR 1mn was reported in 2Q25 compared to expenses of SAR 7mn in 2Q24. As a result, operating profit rose 11.4% YoY to SAR 109mn, with EBIT margin improving 70bps YoY to 13.2%. EBITDA margin expanded by 230bps YoY to 22.4%. Treasury income rose 23% YoY due to higher deposits, while results from joint ventures showed a SAR 1mn loss versus a SAR 8mn profit in 2Q24. Finance costs increased 42% YoY, mainly due to higher lease-related interest expenses. Net income grew 3% YoY to SAR 115mn, though net margin slipped 30bps YoY to 13.9% as topline growth was partly offset by higher finance costs and JV losses. The profit and margins were broadly in line with our forecasts. For 1H25, profit increased 2.6% YoY to SAR 219mn. NADEC announced that it will not distribute dividends for 2025, contrary to our expectations which was disappointing.

Outlook and valuation: NADEC's expansion strategy focuses on strengthening its presence across markets and food sectors through infrastructure upgrades, expanded storage capacity, and modernization of storage and distribution systems. The protein segment is expected to benefit in 2H25 from value-added beef products once the company's slaughterhouse becomes operational in 4Q25. The agriculture segment should also gain from the delivery of 65k tons of wheat in 2H25. Based on the current results we have revised our revenue estimate slightly downwards to SAR 3.51bn (vs SAR 3.56bn) and net profit to SAR 428mn (vs SAR 454mn). However, we remain cautious as the core dairy and food segment continues to show sluggish revenue. Accordingly, we lower our target price to SAR 22.5/share (from SAR 23.9/share), representing an 8.75% upside potential. We therefore downgrade our rating to HOLD from BUY. The stock is currently trading at 14.6x its 2025e EPS.




Revenue growth driven by agri & protein segment




Net margin declines on higher finance costs




Dairy & food revenue flattish on shift in demand



Agriculture revenue spikes on higher sales



Dairy and food margins improves by 90bps YoY



Margins improvement evident in 2Q25





Income statement (in SAR Mn)	2021	2022	2023	2024	2025e	2026e	2027e	2028e
Revenue	2,272	2,694	3,197	3,220	3,515	3,693	3,878	3,911
Direct Costs	-1,641	-1,886	-2,013	-2,028	-2,269	-2,327	-2,443	-2,464
Gross Profit	631	808	1,184	1,192	1,245	1,366	1,435	1,447
Selling and marketing expenses	-484	-488	-560	-532	-550	-609	-640	-665
General and administrative expenses	-148	-139	-213	-235	-234	-259	-271	-274
Provisions on recievables/other	-152	-21	-73	-4	-20	-18	-19	-20
Other Income / (expenses) - net	-58	-13	6	-32	-26	-37	-39	-39
EBIT	-213	147	345	389	416	443	465	450
EBITDA	-1	375	572	636	715	759	786	761
Share of results of joint venture	-	3	22	24	-2	30	30	30
Finance costs	-32	-49	-76	-34	-47	-35	-33	-32
PBT	-245	101	290	827	472	479	502	488
Zakat	-40	-6	-14	-53	-44	-43	-45	-44
Net Profit	-285	95	302	775	428	436	457	444
Balance Sheet (in SAR Mn)	2021	2022	2023	2024	2025e	2026e	2027e	2028e
Property, plant and equipment	1,810	1,713	1,761	1,775	1,959	2,014	2,072	2,125
Right-of-use assets	71	56	58	46	361	292	225	174
Biological assets	686	735	728	696	677	677	677	677
Other non current assets	178	203	149	302	396	396	396	396
Total non-current assets	2,745	2,707	2,695	2,819	3,393	3,378	3,369	3,371
Current inventories	452	516	560	662	635	651	684	690
Trade and other current receivables	288	371	464	472	422	443	465	469
Cash and bank balances	82	113	835	1,365	1,672	1,988	2,201	2,387
Other current assets	323	115	57	85	178	178	178	178
Total current assets	1,145	1,115	2,415	2,885	2,907	3,260	3,528	3,724
TOTAL ASSETS	3,890	3,822	5,110	5,704	6,300	6,638	6,898	7,096
Share capital	1,016	1,016	3,016	3,016	3,016	3,016	3,016	3,016
Reserves	210	223	233	164	-68	-68	-68	-68
Retained earnings	-30	56	344	1,116	1,544	1,980	2,219	2,435
Total Equity attributable to shareholders	1,196	1,295	3,593	4,297	4,472	4,907	5,147	5,362
Total equity	1,196	1,295	3,593	4,297	4,472	4,907	5,147	5,362
Murabaha loans and borrowings	1,150	893	98	2	1	1	1	1
Lease liabilities	45	39	35	26	175	117	91	71
Employee benefit obligation	163	153	148	131	140	155	163	164
Other non current liabilities	5	5	4	3	3	3	3	3
Total non-current liabilities	1,364	1,090	284	162	399	276	258	240
Trade and other current payables	714	678	775	823	976	1,000	1,051	1,059
Murabaha loans and borrowings	486	633	279	206	276	276	276	276
Lease liabilities	25	16	18	14	44	50	39	31
Other current liabilities	105	110	78	119	45	45	45	45
Total current liabilities	1,330	1,437	1,232	1,245	1,429	1,455	1,493	1,494
Total liabilities	2,694	2,526	1,517	1,407	1,828	1,731	1,751	1,734
Total equity and liabilities	3,890	3,822	5,110	5,704	6,300	6,638	6,898	7,096
Cash Flow (in SAR Mn)	2021	2022	2023	2024	2025e	2026e	2027e	2028e
Cash from operations	256	452	655	670	1,056	824	861	839
Investing cash flow	-325	-243	-757	82	-351	-222	-233	-235
Financing cash flow	82	-178	825	-221	-398	-287	-415	-419
Change in cash	13	31	722	531	307	316	213	186
Beginning cash	69	82	113	835	1,365	1,672	1,988	2,201
Ending cash	82	113	835	1,365	1,672	1,988	2,201	2,387



Ratio Analysis	2021	2022	2023	2024	2025e	2026e	2027e	2028e
Per Share								
EPS (SAR)	-2.8	0.9	1.0	2.6	1.4	1.4	1.5	1.5
BVPS (SAR)	11.8	12.7	11.9	14.2	14.8	16.3	17.1	17.8
DPS (SAR)	-	-	-	-	-	0.7	0.8	0.7
FCF per share (SAR)	-0.7	2.1	-0.3	2.5	2.3	2.0	2.1	2.0
Valuation								
Market Cap (SAR Mn)	3,085	2,075	8,401	7,444	6,241	6,241	6,241	6,241
EV (SAR Mn)	4,710	3,544	7,995	6,326	5,065	4,697	4,446	4,232
EBITDA	-1	375	572	636	715	759	786	761
P/E (x)	-10.8	21.7	27.8	9.6	14.6	14.3	13.7	14.1
EV/EBITDA (x)	-	9.4	14.0	9.9	7.1	6.2	5.7	5.6
Price/Book (x)	2.6	1.6	2.3	1.7	1.4	1.3	1.2	1.2
Dividend Yield (%)			0.0%	0.0%	0.0%	3.5%	3.7%	3.6%
Price to sales (x)	1.4	8.0	2.6	2.3	1.8	1.7	1.6	1.6
EV to sales (x)	2.1	1.3	2.5	2.0	1.4	1.3	1.1	1.1
Liqiudity								
Cash Ratio (x)	0.1	0.1	0.7	1.1	1.2	1.4	1.5	1.6
Current Ratio (x)	0.9	0.8	2.0	2.3	2.0	2.2	2.4	2.5
Quick Ratio (x)	0.5	0.4	1.5	1.8	1.6	1.8	1.9	2.0
Returns Ratio								
ROA (%)	-7.3%	2.5%	5.9%	13.6%	6.8%	6.6%	6.6%	6.3%
ROE (%)	-23.8%	7.4%	8.4%	18.0%	9.6%	8.9%	8.9%	8.3%
ROCE (%)	-11.1%	4.0%	7.8%	17.4%	8.8%	8.4%	8.5%	7.9%
Cash Cycle								
Inventory turnover (x)	3.6	3.7	3.6	3.1	3.6	3.6	3.6	3.6
Accounts Payable turnover (x)	2.3	2.8	2.6	2.5	2.3	2.3	2.3	2.3
Receivables turnover (x)	7.9	7.3	6.9	6.8	8.3	8.3	8.3	8.3
Inventory days	101	100	101	119	102	102	102	102
Payable Days	159	131	140	148	157	157	157	157
Receivables days	46	50	53	54	44	44	44	44
Cash Cycle	-12	19	14	25	-11	-11	-11	-11
Profitability Ratio								
Net Margins (%)	-12.5%	3.5%	9.4%	24.1%	12.2%	11.8%	11.8%	11.4%
EBITDA Margins (%)	0.0%	13.9%	17.9%	19.7%	20.3%	20.5%	20.3%	19.5%
PBT Margins (%)	-10.8%	3.8%	9.1%	25.7%	13.4%	13.0%	13.0%	12.5%
EBIT Margins (%)	-9.4%	5.5%	10.8%	12.1%	11.8%	12.0%	12.0%	11.5%
Effective Tax Rate (%)	-16.2%	5.9%	4.9%	6.3%	9.3%	9.0%	9.0%	9.0%
Leverage								
Total Debt (SAR Mn)	1,707	1,581	429	247	496	444	406	379
Net Debt (SAR Mn)	1,625	1,468	-406	-1,118	-1,176	-1,544	-1,795	-2,009
Debt/Equity (x)	1.4	1.2	0.1	0.1	0.1	0.1	0.08	0.07
Net Debt/Equity (x)	1.4	1.1	-0.1	-0.3	-0.3	-0.3	-0.3	-0.4



Key contacts

Research Team

Joice Mathew

Sr. Manager - Research

E-Mail: joice@usoman.com

Tel: +968 2476 3311

Manna Thomas ACCA Research Associate

Email: manna.t@usoman.com


Tel: +968 2476 3347

Contact Address

P. O Box: 2566; P C 112

Sultanate of Oman Tel: +968 2476 3300

Rating Criteria and Definitions Rating Definitions



Rating Defin	itions
Ctrong Buy	This recommendation is used for stocks whose surrent market price
Strong Buy	This recommendation is used for stocks whose current market price
	offers a deep discount to our 12-Month target price and has an
	upside potential in excess of 20%
Buy	This recommendation is used for stocks whose current market price
	offers a discount to our 12-Month target price and has an upside
	potential between 10% to 20%
Hold	This recommendation is used for stocks whose current market price
	offers a discount to our 12-Month target price and has an upside
	potential between 0% to 10%
Neutral	This recommendation is used for stocks whose current market price
	offers a premium to our 12-Month target price and has a downside
	side potential between 0% to -10%
Sell	This recommendation is used for stocks whose current market price
	offers a premium to our 12-Month target price and has a downside
	side potential between -10% to -20%
Strong Sell	This recommendation is used for stocks whose current market price
•	offers a premium to our 12-Month target price and has a downside
	side potential in excess of 20%
Not rated	This recommendation used for stocks which does not form part of
	Coverage Universe
	-

Disclaimer

This document is not for public distribution and has been furnished to you solely for your information and must not be reproduced or redistributed to any other person. Persons into whose possession this document may come are required to observe these restrictions. Opinion expressed is our current opinion as of the date appearing on this material only. We do not undertake to advise you as to any change of our views expressed in this document. While we endeavor to update on a reasonable basis the information discussed in this material, United Securities, its subsidiaries and associated companies, their directors and employees are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that prevent us from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. The information in this document has been printed on the basis of publicly available information, internal data and other reliable sources believed to be true and are for general guidance only. While every effort is made to ensure the accuracy and completeness of information contained, the company takes no guarantee and assumes no liability for any errors or omissions of the information. No one can use the information as the basis for any claim, demand or cause of action.

Recipients of this material should rely on their own investigations and take their own professional advice. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult their own advisors to determine the merits and risks of such an investment. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. United Securities LLC, and affiliates, including the analyst who has issued this report, may, on the date of this report, and from time to time, have long or short positions in, and buy or sell the securities of the companies mentioned herein or engage in any other transaction involving such securities and earn brokerage or compensation or act as advisor or have other potential conflict of interest with respect to company/ies mentioned herein or inconsistent with any recommendation and related information and opinions. United Securities LLC and affiliates may seek to provide or have engaged in providing corporate finance, investment banking or other advisory services in a merger or specific transaction to the companies referred to in this report, as on the date of this report or in the past.